PHI with malignant hepatoma
How does this condition affect your private health insurance?
Malignant hepatoma, or Hepatocellular Carcinoma (HCC), is the most common primary liver cancer, predominantly arising in individuals with chronic liver disease, particularly cirrhosis. Common causes include hepatitis B or C viral infections, excessive alcohol consumption, and non-alcoholic fatty liver disease (NAFLD). HCC is an aggressive cancer, often progressing without early specific symptoms, leading to late diagnosis. Treatment involves surgery, liver transplantation, locoregional therapies (e.g., embolization, ablation), and systemic treatments. Prognosis is generally poor, especially in advanced stages, due to the underlying liver disease and high recurrence rates, significantly impacting liver function and overall health.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Weeks to months from symptom onset to diagnosis and initial treatment phase.
Duration of Illness (Lifetime)
Chronic, with high risk of recurrence even after initial treatment; often life-long management of liver disease.
Cost of Treatment (Initial)
Very high, ranging from tens of thousands to hundreds of thousands of dollars for surgery, transplantation, or advanced therapies.
Cost of Treatment (Lifetime)
Extremely high, due to ongoing surveillance, potential for multiple treatments, and management of underlying liver disease, often exceeding half a million dollars.
Mortality Rate
High, with a 5-year survival rate often below 20% for all stages combined, significantly lower for advanced disease.
Risk of Secondary Damages
Very high, including liver failure, metastasis to other organs, complications from cirrhosis, and significant physical and psychological impact from disease and treatment.
Probability of Full Recovery
Low, estimated at 10-30% for early-stage disease amenable to curative therapies like transplantation or resection, but recurrence is common. Very low for advanced stages.
Underlying Disease Risk
Extremely high, over 80-90% of HCC cases develop in the context of cirrhosis, often caused by chronic viral hepatitis (B or C), alcoholic liver disease, or NAFLD.